Working… Menu
Trial record 2 of 165 for:    "Primary Central Nervous System Lymphoma"

MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02399189
Recruitment Status : Unknown
Verified April 2015 by Jun Zhu, Peking University.
Recruitment status was:  Recruiting
First Posted : March 26, 2015
Last Update Posted : April 13, 2015
Information provided by (Responsible Party):
Jun Zhu, Peking University

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of chemotherapy with MT-R followed by autologous stem cells transplantation in newly-diagnosed primary central nervous system lymphoma.

Condition or disease Intervention/treatment Phase
Primary Central Nervous System Lymphoma Drug: R-MT followed by auto-HSCT Phase 2

Detailed Description:
It's a single center, single arm, prospective clinical trial. Patients younger than 65 years old with primary central nervous system lymphoma will received four cycles of chemotherapy with rituximab plus high-dose methotrexate and temozolomide as induction therapy, and then received consolidation therapy with autologous stem cell transplant for which the conditioning regimen is Carmustine plus thiotepa.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma
Study Start Date : May 2014
Estimated Primary Completion Date : April 2017
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: R-MT followed by auto-HSCT

R-MT followed by auto-HSCT Rituximab 375 mg/m2 d1 MTX 3.5g/m2 d2(0.5g/m2 15min,3g/m2 3h) TMZ 100 mg/m2 d2-6 Q21d*4cycles

Auto-HSCT conditioning regimen:

BCNU 400mg/m2 d1; Thiotepa 5mg/kg q12h,d2-3

Drug: R-MT followed by auto-HSCT
Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
Other Names:
  • Methotrexate(M)
  • Temozolomide(T)
  • Rituximab(R)

Primary Outcome Measures :
  1. progression-free survival [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. overall response rate [ Time Frame: 2 years ]
  2. overall survival [ Time Frame: 2 years ]
  3. event-free survival [ Time Frame: 2 years ]

Other Outcome Measures:
  1. neurotoxicity [ Time Frame: 2 years ]
    using a battery of cognitive and quality-of-life (QoL) measures

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • primary central nervous system diffuse large B-cell lymphoma histologically confirmed by brain biopsy
  • ECOG 0-2
  • Absence of systemic disease as evaluated by chest-abdomen-pelvis CT scan
  • Leucocytes>3.500/mm3, platelets>130.000/mm3, Bilirubin < 2 mg, transaminases < 2.5 N), creatinine < 150 μM/l, creatinine clearance > 50 ml/min/1.73m2
  • Age 18-65 years
  • Negative HIV test
  • Signature of informed consent

Exclusion Criteria:

  • prior chemotherapy for primary central nervous system lymphoma
  • presence of another cancer (excepting basal cell carcinoma of the skin and cervical carcinoma in situ )
  • systemic lymphoma (outside the CNS)
  • Isolated ocular lymphoma
  • Immunosuppressed patients (HIV , use of immunosuppressors)
  • Other uncontrolled or progressive disease compromising shot-term survival
  • Severe renal or hepatic disease
  • Patients not legally covered by the French Social Security
  • Inability to swallow the medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02399189

Layout table for location contacts
Contact: lijuan deng, MD 1099196109
Contact: Yuqin Song, MD 1088196109

Layout table for location information
China, Beijing
Lijuan Deng Recruiting
Beijing, Beijing, China, 100142
Contact: Lijuan Deng, MD    1088196109   
Contact: Yuqin Song, MD    1088196109   
Sponsors and Collaborators
Jun Zhu
Layout table for investigator information
Study Chair: Jun Zhu, MD Beijing Cancer Hospital

Publications of Results:
Layout table for additonal information
Responsible Party: Jun Zhu, Chief of the department of lymphoma, Peking University Identifier: NCT02399189     History of Changes
Other Study ID Numbers: 20150301
First Posted: March 26, 2015    Key Record Dates
Last Update Posted: April 13, 2015
Last Verified: April 2015
Keywords provided by Jun Zhu, Peking University:
Primary central nervous system lymphoma
Methotrexate and Temozolomide
autologous stem cell transplantation
Carmustine and thiotepa
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Nucleic Acid Synthesis Inhibitors
Antineoplastic Agents, Alkylating
Alkylating Agents